BST — Biotechnology Assets SA Share Price
Last trade - 00:00- €21.02m
- €22.51m
- €3.60m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.85 | ||
| Price to Tang. Book | 23.26 | ||
| Price to Free Cashflow | 51.09 | ||
| Price to Sales | 6.88 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -17.22% | ||
| Return on Equity | -39.97% | ||
| Operating Margin | -65.79% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 2.13 | 2.52 | 3.09 | 2.61 | 3.6 | n/a | n/a | -31.17% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Biotechnology Assets SA, formerly known as ADL Bionatur Solutions SA, is a Spain-based biotech company. The Company's main activities are: Research, development and production of biotechnological solutions aimed at improving the health and welfare of people and animals; Development, acquisition, transfer and exploitation of industrial and intellectual property rights; Distribution, marketing, export and import of the previously mentioned products. The Company's purpose is the acquisition and promotion of real estate of an urban nature for lease through the ownership of assets directly, through companies with this purpose, with the holding of shares in the capital of other entities, resident or not in the Spanish territory, or through collective investment vehicles.
Directors
- Victor Vinolo CHM
- Jose Martin CFO
- Felix Risco CTO
- Juan Jose Infante CSO
- Rosa Osuna DGM
- Francisco Bascon Romero OTH
- Ana de las Heras OTH
- Rocio Molina OTH
- Rafael Jesus Contreras Chamorro DRC
- Emilio Moraleda Martinez DRC
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- March 1st, 2005
- Public Since
- June 14th, 2011
- No. of Employees
- 38
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Madrid Stock Exchange
- Shares in Issue
- 66,942,702
- Address
- Av. del Desarrollo Tecnologico, 11, JEREZ DE LA FRONTERA, 11591
- Web
- https://biatgroup.com/es/
- Phone
- +34 856060603
- Auditors
- Auren Auditores MAD, S.L.
Upcoming Events for BST
Similar to BST
1nkemia IUCT SA
Madrid Stock Exchange
ORYZON Genomics SA
Madrid Stock Exchange
Pangaea Oncology SA
Madrid Stock Exchange
FAQ
As of Today at 19:36 UTC, shares in Biotechnology Assets SA are trading at €0.31. This share price information is delayed by 15 minutes.
Shares in Biotechnology Assets SA last closed at €0.31 and the price had moved by -11.55% over the past 365 days. In terms of relative price strength the Biotechnology Assets SA share price has underperformed the FTSE Global All Cap Index by -13.76% over the past year.
The overall consensus recommendation for Biotechnology Assets SA is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreBiotechnology Assets SA does not currently pay a dividend.
Biotechnology Assets SA does not currently pay a dividend.
Biotechnology Assets SA does not currently pay a dividend.
To buy shares in Biotechnology Assets SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of €0.31, shares in Biotechnology Assets SA had a market capitalisation of €21.02m.
Here are the trading details for Biotechnology Assets SA:
- Country of listing: Spain
- Exchange: MCE
- Ticker Symbol: BST
Based on an overall assessment of its quality, value and momentum Biotechnology Assets SA is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Biotechnology Assets SA is €3.10. That is 887.26% above the last closing price of €0.31.
Analysts covering Biotechnology Assets SA currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biotechnology Assets SA. Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +7.03%.
As of the last closing price of €0.31, shares in Biotechnology Assets SA were trading -0.95% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Biotechnology Assets SA PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at €0.31.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Biotechnology Assets SA's management team is headed by:
- Victor Vinolo - CHM
- Jose Martin - CFO
- Felix Risco - CTO
- Juan Jose Infante - CSO
- Rosa Osuna - DGM
- Francisco Bascon Romero - OTH
- Ana de las Heras - OTH
- Rocio Molina - OTH
- Rafael Jesus Contreras Chamorro - DRC
- Emilio Moraleda Martinez - DRC